BLAINJECTIONINJECTABLE
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
VEGZELMA (bevacizumab-adcd) by Celltrion is vascular endothelial growth factor-directed antibody interactions [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2022.
Drug data last refreshed 13h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VEGZELMA is a bevacizumab-adcd biosimilar antibody-drug conjugate (ADC) approved by FDA on September 27, 2022, developed by Celltrion. It targets vascular endothelial growth factor (VEGF) to inhibit angiogenesis and is used across multiple oncology and ophthalmology indications. The ADC modality combines VEGF inhibition with cytotoxic payload delivery for enhanced anti-tumor activity.
Peak
VEGZELMA is in peak commercial phase with moderate competitive pressure (30/100), indicating active growth phase requiring robust commercial infrastructure and sales force expansion.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on VEGZELMA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.